Literature DB >> 33859786

Novel Azaquinolones as PARP1 Inhibitors for Treating Cancer.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2021        PMID： 33859786      PMCID： PMC8040051          DOI： 10.1021/acsmedchemlett.1c00122

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  5 in total

Review 1.  The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.

Authors:  Yue Zhao; Liu-Xia Zhang; Ting Jiang; Jing Long; Zhong-Ye Ma; Ai-Ping Lu; Yan Cheng; Dong-Sheng Cao
Journal:  Eur J Med Chem       Date:  2020-07-15       Impact factor: 6.514

Review 2.  Therapeutic Application of PARP Inhibitors in Neuro-Oncology.

Authors:  Jianfang Ning; Hiroaki Wakimoto
Journal:  Trends Cancer       Date:  2020-01-13

Review 3.  PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.

Authors:  Heng Zhu; Miaoyan Wei; Jin Xu; Jie Hua; Chen Liang; Qingcai Meng; Yiyin Zhang; Jiang Liu; Bo Zhang; Xianjun Yu; Si Shi
Journal:  Mol Cancer       Date:  2020-03-02       Impact factor: 27.401

Review 4.  Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers.

Authors:  Dawn C Janysek; Jennifer Kim; Pascal H G Duijf; Eloïse Dray
Journal:  Transl Oncol       Date:  2021-01-27       Impact factor: 4.243

Review 5.  PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.

Authors:  Claire Fritz; Scott M Portwood; Amanda Przespolewski; Eunice S Wang
Journal:  Blood Rev       Date:  2020-05-07       Impact factor: 10.626
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.